BTK Inhibition as a Strategy for CSU Treatment

Author(s):

Giselle Mosnaim, MD, MS ,Shyam Joshi, MD

Panelists discuss how Bruton tyrosine kinase (BTK) inhibition could effectively treat both autoallergic and autoimmune chronic spontaneous urticaria (CSU).

EP: 1.Chronic Spontaneous Urticaria and Bruton Tyrosine Kinase: A Multispecialty Expert Discussion

EP: 2.Pathophysiology of Chronic Spontaneous Urticaria

EP: 3.Current CSU Treatment Approach and the Role of Bruton Tyrosine Kinase

Now Viewing

EP: 4.BTK Inhibition as a Strategy for CSU Treatment

EP: 5.How BTK Inhibitors Differ From Current CSU Treatment Approaches

Video content above is prompted by the following:

• How would targeting BTK through inhibition be a strategy in the treatment of both IgE (autoallergic) and IgG (autoimmune) CSU?
• Covalent binding enables high and sustained occupancy of BTK without the need for sustained systemic exposure.